Combinatorial approaches for treating neuropsychiatric social impairment

Philos Trans R Soc Lond B Biol Sci. 2022 Aug 29;377(1858):20210051. doi: 10.1098/rstb.2021.0051. Epub 2022 Jul 11.

Abstract

Social behaviour is an essential component of human life and deficits in social function are seen across multiple psychiatric conditions with high morbidity. However, there are currently no FDA-approved treatments for social dysfunction. Since social cognition and behaviour rely on multiple signalling processes acting in concert across various neural networks, treatments aimed at social function may inherently require a combinatorial approach. Here, we describe the social neurobiology of the oxytocin and endocannabinoid signalling systems as well as translational evidence for their use in treating symptoms in the social domain. We leverage this systems neurobiology to propose a network-based framework that involves pharmacology, psychotherapy, non-invasive brain stimulation and social skills training to combinatorially target trans-diagnostic social impairment. Lastly, we discuss the combined use of oxytocin and endocannabinoids within our proposed framework as an illustrative strategy to treat specific aspects of social function. Using this framework provides a roadmap for actionable treatment strategies for neuropsychiatric social impairment. This article is part of the theme issue 'Interplays between oxytocin and other neuromodulators in shaping complex social behaviours'.

Keywords: combinatorial; endocannabinoids; oxytocin; social behaviour; social cognition.

Publication types

  • Review

MeSH terms

  • Humans
  • Mental Disorders* / therapy
  • Oxytocin*
  • Social Behavior

Substances

  • Oxytocin